lhrh, gln(8)- has been researched along with Multiple Myeloma in 1 studies
*Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bjorklund, CC; Chang, CC; Feng, Y; Liao, B; O'Hare, J; Orlowski, RZ; Schally, AV; Shi, ZZ; Wang, M; Wen, J; Zu, Y | 1 |
1 other study(ies) available for lhrh, gln(8)- and Multiple Myeloma
| Article | Year |
|---|---|
Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Down-Regulation; Female; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Phosphorylation; Pyrrolidonecarboxylic Acid; Transfection; Xenograft Model Antitumor Assays | 2011 |